Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis
Authors:
- 1 September 2020
- journal article
- review article
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 128, 68-74
Abstract
No abstract availableKeywords
Funding Information
- Health and Labor Sciences Research (19GC1012)
- Eisai Co., Ltd. (112–8088)
This publication has 18 references indexed in Scilit:
- Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical TrialsBiological Psychiatry, 2016
- Suvorexant: The first orexin receptor antagonist to treat insomniaJournal of Pharmacology and Pharmacotherapeutics, 2015
- Evaluating the Quality of Evidence from a Network Meta-AnalysisPLOS ONE, 2014
- Understanding the Sleep-Wake Cycle: Sleep, Insomnia, and the Orexin SystemThe Journal of Clinical Psychiatry, 2013
- Insomnia PharmacotherapyNeurotherapeutics, 2012
- ACS Chemical Neuroscience Molecule Spotlight on SuvorexantACS Chemical Neuroscience, 2012
- Insomnia and the Performance of US Workers: Results from the America Insomnia SurveySLEEP, 2011
- Critical appraisal of ramelteon in the treatment of insomniaNature and Science of Sleep, 2010
- Distinct Narcolepsy Syndromes in Orexin Receptor-2 and Orexin Null MiceNeuron, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986